Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Avenue Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 21 | 18 | −3 |
| Shares | 1.09M | 2.36M | +1.27M (+116.8%) |
| Value | $1.62M | $2.14M | +$519.9K (+32.0%) |
New holders (2)
Institutions that held Avenue Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 20,036 | $18.0K | 0.00% |
| Warberg Asset Management LLC | 10,001 | $9.00K | 0.00% |
Sold out (5)
Institutions that held Avenue Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Renaissance Technologies LLC | 118,100 | $176.0K |
| Kestra Advisory Services, LLC | 22,500 | $34.0K |
| HRT Financial LP | 19,704 | $29.0K |
| Barclays PLC | 1,125 | $2.00K |
| Capital Analysts, LLC | 601 | $1.00K |